Company news
Shanghai Shyndec Pharmaceutical Co., Ltd. news in 2026
Shanghai Shyndec Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2026, newest first.
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
November 13, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Controlled Subsidiary Passing the Drug GMP Compliance Inspection
November 9, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Withdrawal of Drug Registration Application by Controlled Subsidiary
November 5, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
November 5, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction
November 4, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Report for Q3 2026
October 30, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Resolutions of the 9th Meeting of the 9th Board of Directors
October 30, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Departure of Director and By-election of Director
October 30, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Progress of Signing of the Drug Marketing Authorization Transfer Contract by Controlled Subsidiary
October 22, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
October 22, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
October 15, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Performance Forecast for the First Three Quarters of 2026
October 14, 2026
(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
September 29, 2026
Announcement on Progress of Provision of Guarantees by a Wholly-owned Subsidiary to Its Subordinate Enterprise
September 11, 2026
Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 10, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 2, 2026
Announcement on the Wholly-Owned Subsidiary's Receipt of the Approval Notice for the Marketing Application of a Chemical API
August 27, 2026
Announcement on Resolutions of the 8th Meeting of the 9th Board of Directors
August 26, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
August 19, 2026
Announcement on Wholly-owned Sub-subsidiary Obtaining Approval for Marketing of Chemical APIs
August 4, 2026
Announcement on Resolutions of the 6th Meeting of the 9th Board of Directors
August 3, 2026
Announcement on Progress of Signing of the "Drug Marketing Authorization Transfer Contract" by a Controlled Subsidiary
July 30, 2026
Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
July 24, 2026
Announcement on Obtaining Drug Registration Certificate
July 23, 2026
Announcement on the Wholly-owned Subsidiary's Drug Passing Generic Drug Consistency Evaluation
July 13, 2026
Semi-annual Performance Forecast for 2026
July 10, 2026
Announcement on Resolutions of the 5th Meeting of the 9th Board of Directors
June 30, 2026
Announcement on Holding Subsidiary Obtaining Drug Registration Certificate
June 25, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
June 23, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 25, 2026
Announcement on Obtaining Drug Registration Certificate
May 21, 2026
Announcement on Wholly-owned Subsidiary's Drug Substance Obtaining Indian Registration Certificate
May 11, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 8, 2026
Report for Q1 2026
April 29, 2026
Announcement on Progress in Providing Guarantees for Subsidiaries
April 15, 2026
Earnings Preannouncement for Q1 2026
April 10, 2026
Announcement on Voluntary Information Disclosure of Wholly-owned Subsidiary's Drug Passing Consistency Evaluation for Generic Drugs
April 3, 2026
Announcement on Estimated Daily Related Party Transactions in 2026
March 27, 2026
by Holding Subsidiary
March 24, 2026
Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
March 3, 2026
Announcement on Wholly-owned Sub-subsidiary Obtaining Approval for Marketing of Chemical APIs
February 24, 2026
Announcement on Proposed Selection of Partial Drugs for Continuation Procurement Under National Procurement Scheme After Agreement Expiry
February 11, 2026
Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
February 9, 2026
Announcement on Provision for Impairment
January 26, 2026